NCT03564379

A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants

A Double-blind, Placebo-controlled, Randomized, Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: Male
• Age: 20 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of JNJ-42165279 in healthy Japanese male participants after single and multiple oral dose administration.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	JNJ-42165279	25 mg JNJ-42165279 tablet will be administered orally.
DRUG	Placebo	Matching placebo tablet will be administered orally.

Timeline

• Start date: 2018-06-12
• Primary completion: 2018-08-13
• Completion: 2018-08-13
• First posted: 2018-06-20
• Last updated: 2025-04-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study